Gilead to buy PepStar's inflammation drug program in $1.28 billion deal
GILD•Gilead Sciences will acquire PepStar Therapeutics' oral inflammation drug program for $1.275 billion in cash, including an experimental bowel disease treatment.
1. Drug program acquisition
Gilead Sciences said it will acquire PepStar Therapeutics' oral inflammation drug program for $1.275 billion in cash. The program includes HCXT-2001, an experimental oral treatment for inflammatory bowel disease that acts on the IL-23 pathway and is in early-stage clinical testing.
